Home Drug Codes NOC Codes AVOPEF
HCPCS Unassigned

AVOPEF

See the Announcement
Miscellaneous Code ?
J9999
bill now · NOC code
WAC ?
$400.00
per 100 MG / 5 ML
AWP ?
$480.00
per 100 MG / 5 ML
Part B Reference ?
$412.00
up to 103% of WAC
NDCs Listed ?
2
View NDC details →

AVOPEF currently does not have a permanent HCPCS code and should be billed using a miscellaneous code.

Drug & Product Overview

Proposed Billing Descriptor Available at HCPCS code assignment
Miscellaneous Billing Code J9999
FDA Approval Date February 13, 2026
Manufacturer Avyxa Pharma
Route of Administration Intravenous
Dosage Type Multi-Dose
Dosage Form Injection

How to Bill AVOPEF Now

Until CMS assigns a permanent product-specific code, bill this drug with a miscellaneous / not-otherwise-classified (NOC) code and identify the product by its NDC and package details. A NOC code is only valid while no product-specific code exists; once a permanent code is effective, NOC claims for this drug will deny.

Setting Claim Form Billing Code Notes
Physician office / Part B CMS-1500 / 837P J9999 Enter the drug name and dosage in Item 19 (or the 837P equivalent). The claim is manually priced by the MAC.
Hospital outpatient (OPPS) UB-04 / 837I C9399 Unclassified/NOC drug or biological. Separately payable and manually priced by the MAC using AWP-based methodology.
Required Claim Documentation
Drug name and dosage administered National Drug Code (NDC) of the product given Total quantity administered, in the applicable unit of measure Date the drug was administered

WAC pricing is not required for the claim, but a payer may reference it as a benchmark when manually pricing a NOC-coded drug.

About AVOPEF

AVOPEF (etoposide) is a provider-administered antineoplastic injection from Avyxa Pharma, given by intravenous infusion. Etoposide is a topoisomerase II inhibitor used in the treatment of certain cancers. As a newly launched product, AVOPEF does not yet have its own permanent product-specific HCPCS code; CMS assigns and crosswalks permanent drug codes on a quarterly cycle, so a product-specific code commonly takes several months to a year after launch.

Until then, AVOPEF is billed with the not-otherwise-classified antineoplastic code (J9999), identifying the product by its NDC, dosage, and units. A NOC code is valid only while no product-specific code applies to the NDC; once one is effective, NOC claims for this product will deny. See the Billing Guidance below for how to bill it in each setting, plus NDC pricing, WAC/AWP references, and the anticipated permanent code.

NDC Code Information

Identify the product on the claim by its NDC and package details. The list of NDCs below is not exhaustive.

NDC Code Package Manufacturer WAC AWP
83831-0144-05
100 MG / 5 ML One Multiple-Dose Vial 100mg/5mL (20mg/mL)
AVYXA Pharma LLC $400.00 $480.00
83831-0145-25
500 MG / 25 ML One Multiple-Dose Vial 500mg/25mL (20mg/mL)
AVYXA Pharma LLC $2,000.00 $2,400.00

Effective 4/1/26 (WAC & AWP)

AVOPEF Pricing & Reimbursement

No ASP-based Medicare payment limit exists until a permanent code is assigned. The figures below are published list-price benchmarks and initial-period references.

Package (NDC)
WAC Wholesale Acquisition Cost · per package
$400.00
AWP Average Wholesale Price · per package
$480.00
Part B Reference up to 103% of WAC · initial sales period
$412.00

Figures reflect NDC 83831-0144-05 — see the NDC table for all packages.

Because no permanent code has been assigned, there is no HCPCS billing unit yet, so pricing is shown per package (per NDC). No ASP-based Medicare payment limit exists. WAC and AWP are published list-price benchmarks, not guaranteed payment; the Part B figure (up to 103% of WAC) is an initial-period reference point, not a payer’s final allowed amount.

Anticipated HCPCS Coding

The permanent product-specific code expected for AVOPEF once CMS completes its review.

Projected
Anticipated HCPCS Code J9186

This is a projection, not a confirmed assignment. CMS reviews and assigns permanent HCPCS codes on a quarterly cycle and does not guarantee a code or effective date in advance. Confirm current coding with CMS and your payer before billing.

AVOPEF Clinical Information

Indications and drug classification.

Treated Diseases & Conditions
Refractory Testicular Cancer Small Cell Lung Cancer
Drug Class
Topoisomerase Inhibitor [EPC]Topoisomerase Inhibitors [MoA]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.

Frequently Asked Questions

Where can I find the billing and coding guide?
Where can I find the full prescribing information?

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.